PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company’s research and development initiatives at two scientific conferences.
The abstracts covered topics such as biosynthetic pathway and transcriptional methodologic development; evaluation; screening and optimization of systems and organisms, and increasing bioproduction yields of natural and non-natural products.
Additional abstracts focused on the evaluation of impulsivity, motivational, psychiatric, and psychoactive effects of PsyBio's portfolio of compounds.
"These recent scientific presentations serve to further expand our contribution to improve mental and neurological health and demonstrate PsyBio's commitment to being a leader in developing psycho-targeted therapeutic candidates," Evan Levine, PsyBio's CEO said in a statement. "Our approach towards collaborative research remains a critical part of our goal."
PsyBio’s chief medical officer Michael Spigarelli commended the joint efforts between PsyBio and its sponsored research collaborators that made the presentations possible.
"PsyBio remains committed to advancing scientific knowledge and dissemination of results while ensuring intellectual property protection," Spigarelli said. "We will continue to collect data and advance the clinical and scientific knowledge base to be able to help improve mental and neurological health."
Ohio- and Florida-based PsyBio is an intellectual property-driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health.